Vertex Pharmaceuticals updates kidney disease programs at ASN Kidney Week 2026 conference

Vertex Pharmaceuticals presented updates on its kidney disease research and development programs at the American Society of Nephrology (ASN) Kidney Week 2026. The event featured discussions on their portfolio, including new data on the AMKD program with inaxaplin and recent findings on povetacicept in IgAN published in the New England Journal of Medicine. Key speakers included Vertex executives and leading nephrology researchers. This highlights Vertex's ongoing commitment to advancing treatments for kidney diseases, with further data and developments expected to follow.

As of Oct 24, 2026 14:41 WIB, Vertex Pharmaceuticals Incorporated (VRTX) trades at USD 523.93 on Pluang, showing a 2.10% decline in the past day. The stock's market capitalization stands at $135.64 billion, with a high sell order activity of 89% compared to 11% buy orders. This trading activity indicates cautious sentiment among Pluang investors despite the company's ongoing kidney disease research updates.